View from the Molecular Level
Combination Drug Approach Aimed at Cancer's Network
By Jennifer Boggs
Monday, November 10, 2008
SAN FRANCISCO - Over the last several years - really starting with the 1998 approval of Herceptin as the first successful targeted therapy to hit the market - cancer has become a more treatable disease. Even so, most of the achievements have come in the form of small disease progression-free increments and limited response rates.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.